Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Aclaris Therapeutics, Inc. (ACRS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "COBRA”), Employer will continue to pay, directly to the healthcare provider when due, Employer’s portion of the medical, vision and dental coverage premiums for a period of twelve months after the effective date of Executive’s termination ; provided that, if at any time Employer determines, in its sole discretion, that the payment of the COBRA 6"
06/01/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
05/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
04/20/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/20/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 ARS Form ARS - Annual Report to Security Holders:
04/14/2023 8-K Quarterly results
03/31/2023 8-K Regulation FD Disclosure  Interactive Data
03/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 1 to Consulting Services Agreement, by and between the Company and Frank Ruffo"
03/16/2023 SC 13G BIOTECHNOLOGY VALUE FUND L P reports a 5% stake in Aclaris Therapeutics, Inc.
03/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Quarterly results
02/14/2023 SC 13G/A Rock Springs Capital Management LP reports a 5.9% stake in Aclaris Therapeutics, Inc.
02/14/2023 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 4.9% stake in Aclaris Therapeutics, Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/31/2023 SC 13G/A BlackRock Inc. reports a 7.6% stake in ACLARIS THERAPEUTICS, INC
01/09/2023 8-K Investor presentation
01/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/13/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Investor presentation, Quarterly results
08/03/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Quarterly results
08/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/03/2022 8-K Quarterly results
05/10/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy